Skip to content

A study on Maantha Ennai and varmam therapy for the treatment of pei mantham (Generalized tonic-clonic seizure)in children

Preclinical and Clinical evaluation of the effect on oral administration of MAANTHA ENNAI and VARMAM THERAPY in the management of PEI MAANTHAM (GENERALIZED TONIC-CLONIC SEIZURE) in paediatric age group - A double arm study - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/103289
Enrollment
40
Registered
2026-02-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G998- Other specified disorders of nervous system in diseases classified elsewhere

Interventions

Intervention1: Maandha Ennai: DOSAGE: 3 5 ml, twice daily for 14 days ROUTE: Oral administration Control Intervention1: Varmam Therapy: Varmam Therapy (External) on specified points (Sirunkoolli, Ucch

Sponsors

Dr T GANESAN
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age 3 12 yrs, 2.febrile seizures, 3.metabolic seizures, 4.CP with seizures.

Exclusion criteria

Exclusion criteria: 1.Brain tumor, 2.Brain trauma, 3.Meningitis, 4.Lead poisoning, 5.Above 12 yrs

Design outcomes

Primary

MeasureTime frame
To validate Siddha interventions in seizure management.To provide evidence for anticonvulsant efficacy of Maandha Ennai.To demonstrate neuromuscular stabilizing potential of Varmam Therapy. - To support integrative pediatric epilepsy care with minimal side effects.Timepoint: The study outcomes related to seizure control, anticonvulsant efficacy, neuromuscular stabilization, and safety will be assessed at predefined time points at baseline (Day 0), during treatment (Day 7), and at the end of treatment (Day 14) to validate Siddha interventions in seizure management, evaluate the anticonvulsant efficacy of Maandha Ennai and the neuromuscular stabilizing potential of Varmam Therapy, and support integrative pediatric epilepsy care with minimal side effects.

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr K SHYAMALA MD S

Government Siddha Medical College and Hospital,Palayamkottai

shyamsujisathya@gmail.com9442277124

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026